All News
Merck announced that it will be laying off 143 people from the Cambridge, Massachusetts-based Acceleron.
Orchard Therapeutics announced today that it intends to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs.
Biogen will await word after submitting the final study protocol for its confirmatory Phase IV ENVISION trial of Aduhelm to the U.S. Food and Drug Administration (FDA).
A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons.
Researchers have developed a new form of UV light that is safe for people but decreased the level of indoor airborne microbes by more than 98% in less than five minutes.
Successfully managing Gen Z employees in the workplace requires knowing about their distinctive traits and the factors that set them apart.
Despite being represented in clinical research, no solutions have been found to circumvent the effects of Alopecia areata. However, there may be hope.
Partner Therapeutics, based in Lexington, Mass., has teamed up with the University of Colorado to study mouse models of Down syndrome and compounds that might improve memory with age.
Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.
After manufacturing more than 2.6 billion doses of the Comirnaty COVID-19 vaccine together, Pfizer’s partner BioNTech is reporting skyrocketing profits.
Vyant Bio and OrganoTherapeutics announced a new partnership between them, with plans to advance research and development efforts in the treatment of Parkinson’s Disease.
Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.
Interim data from Genentech’s first randomized study on a candidate treatment for extensive-stage small-cell lung cancer failed to meet its co-primary endpoint.
Neuron23 announced today that it closed a $100 million Series C financing round led by SoftBank Vision Fund 2.
Data from Clene’s RESCUE-ALS trial showed that treatment with CNM-Au8 significantly slowed progression of ALS and improved quality of life.
Without holding a meeting of its vaccines advisory committee, the U.S. Food and Drug Administration (FDA) authorized a fourth booster shot for everyone 50 years of age and older.
Aldeyra Therapeutics will announce three clinical trials involving ADX-629, its first-in-class oral RASP modulator, at its 2022 Research & Development Day.
New research investigates the role chaperone-mediated autophagy (CMA) can play in preventing atherosclerosis, a thickening or hardening of the arteries.
Antares Pharma has announced that the U.S. Food and Drug Administration has granted approval to its therapeutic Tlando intended for testosterone replacement therapy (TRT).
Lately, there has been heightened attention to briefing documents in the CNS space, a notoriously tricky area to get drugs approved, which can affect company stock prices.